1863-P: Medicare Beneficiaries with Type 1 and Type 2 Diabetes Using the MiniMed 780G System Exceed Glycemic Targets

Introduction and Objective: As many as one-third of Medicare beneficiaries (MCB) have diabetes. The MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system, improves glycemic control in people with T1D and T2D. However, accessing an AID system can be challenging for MCBs due to restrictive C-peptide criteria for durable medical tubed pumps not required with Medicare Part D pharmacy benefit for patch pumps. Methods: De-identified real-world data from United States MM780G users (N=20,123) receiving Medicare and with ≥10 days of Carelink™ data uploaded between January 2023 and October 2025 were analyzed. Glycemic outcomes and insulin delivered were assessed in the overall group and in a cohort (N=5,512) using recommended optimal settings (ROS: 100mg/dL glucose target with an active insulin time [AIT] of 2hrs). Results: Type of diabetes was self-reported as follows: 67.2% with T1D, 17.5% with T2D and 15.2% was unreported/other. Glycemic outcomes and insulin delivered were assessed (Table). Over half achieved ADA composite goals and most (>65%) of the insulin was delivered by the system. Conclusion: Medicare beneficiaries using the MiniMed™ 780G system exceeded recommended TIR goals; greater access to the MiniMed™ 780G system may improve clinical outcomes. Disclosure J. McVean: Employee; Current; Medtronic. M. Liu: Employee; Current; Medtronic. C. Rodriguez: Employee; Current; Medtronic. K.V. Tran: Employee; Current; Medtronic. J.J. Shin: Employee; Current; Medtronic. R. Vigersky: Employee; Current; Medtronic.